{"id":668,"name":"Third Rock Ventures","slug":"third-rock-ventures","website":"https://www.thirdrockventures.com","hqGeo":"Boston, MA","stageFocus":["Pre-Seed","Seed","Series A"],"sectorTags":["Healthcare","Other"],"excludedSectors":[],"checkSizeMin":500000,"checkSizeMax":15000000,"thesisSummary":"Third Rock focuses exclusively on life sciences companies with transformative therapeutic potential, particularly in oncology and precision medicine.","thesisNarrative":null,"logoUrl":null,"aumUsd":3800000000,"submissionUrl":null,"linkedinUrl":null,"twitterHandle":null,"portfolio":[{"companyName":"Allogene Therapeutics","companyUrl":null,"stage":null,"sector":"Cell Therapy","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Neon Therapeutics","companyUrl":null,"stage":null,"sector":"Oncology","investmentYear":null,"description":null,"amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Aqvesme™","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Syremis Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Syremis is developing novel medicines to make a profound impact on the treatment of mental health.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"INLEXZO™","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"INLEXZO™ (gemcitabine intravesical system) an original asset from Taris Bio, receives FDA approval.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Azalea Therapeutics","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Azalea is enabling precision genome engineering directly inside the body, with an initial focus on creating cancer immunotherapies in vivo.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Element Science","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Element Science receives FDA approval for the revolutionary Jewel® Patch Wearable Cardioverter Defibrillator.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"Merida Biosciences","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"Merida is advancing a precision immunology approach for antibody-driven diseases that selectively and durably eliminate their pathogenic drivers.","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RHYTHM METABOLIC, INC.  (RYTM)  (CIK 0001649904)","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"SEC Form D filing mentioning Third Rock Ventures","amountUsd":null,"relevanceNote":null,"fundName":null},{"companyName":"RHYTHM PHARMACEUTICALS, INC.  (RYTM)  (CIK 0001649904)","companyUrl":null,"stage":null,"sector":null,"investmentYear":null,"description":"SEC Form D filing mentioning Third Rock Ventures","amountUsd":null,"relevanceNote":null,"fundName":null}],"partnerCount":11,"partners":[{"id":5889,"name":"Alison Connors","title":"Chief Financial Officer","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/alison-connors-7047987","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5890,"name":"Neil Exter","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/neil-exter-7072a11","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5891,"name":"Jesper Gromada","title":"Venture Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/jesper-gromada-b3787042","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5892,"name":"Abbie Celniker","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/abbie-celniker-277a356","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5893,"name":"Jigar Raythatha","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/jigar-raythatha","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5894,"name":"Reid Huber","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/reid-huber-2374277","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5895,"name":"Richard Ransohoff","title":"Venture Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/richard-ransohoff-9853b4119","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5896,"name":"Lioudmila Tchistiakova","title":"Venture Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/lioudmila-tchistiakova-11b54911","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5897,"name":"David Kaufman","title":"Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/david-kaufman-18b00a19","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":5888,"name":"Mark Goldsmith","title":"Venture Partner","seniority":null,"focusTags":[],"linkedinUrl":"https://www.linkedin.com/in/mark-a-goldsmith-m-d-ph-d-44495451","twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]},{"id":1143,"name":"Christoph Westphal","title":"Founding Partner","seniority":null,"focusTags":["Biotech","Oncology","Cell Therapy"],"linkedinUrl":null,"twitterHandle":null,"blogUrl":null,"thesisSummary":null,"whyThisPartner":null,"recentPosts":[]}],"funds":[],"activity":{"lastInvestmentYear":null,"investmentsLast12Months":0},"investorType":"vc","preferredApproach":"warm intro preferred","prefersFounderType":null,"oneClickPitchEnabled":false,"relatedFirms":[{"id":6492,"name":"Breed Reply","slug":"breed-reply","logoUrl":null,"website":"https://www.reply.com/","stageFocus":[],"sectorTags":["Healthcare","Security"],"hqGeo":null},{"id":6827,"name":"Force Over Mass","slug":"force-over-mass","logoUrl":null,"website":"https://www.fomcap.com/","stageFocus":[],"sectorTags":["AI / ML","Developer Tools","Other","Fintech","SaaS","Healthcare","EdTech"],"hqGeo":null},{"id":1548,"name":"Health Innovation Capital","slug":"health-innovation-capital","logoUrl":null,"website":"https://www.healthinnovation.vc/","stageFocus":["Seed","Pre-Seed"],"sectorTags":["Healthcare"],"hqGeo":"Boston, MA"},{"id":12096,"name":"TeleHealth Ventures","slug":"telehealth-ventures","logoUrl":null,"website":"https://telehealthventures.com","stageFocus":["Seed"],"sectorTags":["Other","Healthcare"],"hqGeo":"Austin, TX"},{"id":1369,"name":"Sonder Health Ventures","slug":"sonder-health-ventures","logoUrl":null,"website":"https://sondercapital.com/","stageFocus":["Pre-Seed","Seed"],"sectorTags":["Healthcare","Other"],"hqGeo":"Austin, TX, USA"},{"id":11533,"name":"Nova Health Fund","slug":"nova-health-fund","logoUrl":null,"website":"https://www.independenthealth.com/","stageFocus":["Seed","Series A"],"sectorTags":["Healthcare","Other"],"hqGeo":"Minneapolis, MN"}],"featuredIn":[{"slug":"pre-seed","displayName":"Pre-Seed Investors","pageType":"stage"},{"slug":"seed","displayName":"Seed Investors","pageType":"stage"},{"slug":"series-a","displayName":"Series A Investors","pageType":"stage"},{"slug":"healthcare","displayName":"Healthcare Investors","pageType":"industry"}],"fundraisingResources":[{"slug":"what-vcs-actually-look-for-pitch-deck","title":"What VCs Actually Look for in a Pitch Deck"},{"slug":"find-right-pre-seed-investors-b2b-saas","title":"How to Find the Right Pre-Seed Investors for Your B2B SaaS Startup"},{"slug":"Finding-Investors-For-Startup-In-2026","title":"How to Find Investors for Your Startup in 2026 (Without Cold-Searching Databases)"}],"overviewNarrative":null,"portfolioNarrative":null,"seoTitle":null,"seoDescription":null,"lastVerifiedAt":"2026-06-19T22:28:45.671Z"}